|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-4-19
|
|
pubmed:abstractText |
Drug-induced phospholipidosis (PL) is a phospholipid storage disorder characterized by the accumulation of multi-lamellar bodies (myeloid bodies) in tissues. A major unanswered question is whether PL represents a benign adaptive response, symptom or early event in drug toxicity. The absence of a non-invasive biomarker to monitor tissue PL has made it difficult to determine the prevalence and implications of PL in the clinic. As a result, the interpretation of PL in risk assessment remains uncertain in preclinical and clinical drug development.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1744-7607
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
555-70
|
|
pubmed:dateRevised |
2011-8-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20370598-Animals,
pubmed-meshheading:20370598-Biological Markers,
pubmed-meshheading:20370598-Drug Design,
pubmed-meshheading:20370598-Humans,
pubmed-meshheading:20370598-Lipidoses,
pubmed-meshheading:20370598-Long QT Syndrome,
pubmed-meshheading:20370598-Lysophospholipids,
pubmed-meshheading:20370598-Monoglycerides,
pubmed-meshheading:20370598-Niemann-Pick Disease, Type C,
pubmed-meshheading:20370598-Pharmaceutical Preparations,
pubmed-meshheading:20370598-Phospholipids,
pubmed-meshheading:20370598-Risk Assessment,
pubmed-meshheading:20370598-Time Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
|
|
pubmed:affiliation |
Nextcea, Inc., 600 West Cummings Park, #6375, Woburn, MA 01801, USA.
|
|
pubmed:publicationType |
Journal Article,
Review
|
